Project Grant R43AI174486
Award Date
8/1/23
Completion Date
7/31/25
Dollars Obligated
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Epivax Inc. (NLAVQM513F18)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rhode Island, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,921 to Ubiquitx Inc., a New York-based biotechnology company, to develop and evaluate a novel therapeutic platform called Chimeric Ligands for Induced Proximity (CLIPS). The goal of this 1-year project is to utilize the CLIPS platform to upregulate the presentation of disease-associated peptide antigens on...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $568,264 to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company, to develop a scalable bioprocess for manufacturing human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of designer RBCs with unique antigen profiles to help identify complex antibodies in...
Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $231,131 to Duquesne University to develop and evaluate injectable 3D-clustered human fibroblastic reticular cells (clFRCs) for expanding regulatory T cells (Tregs) in allograft transplant applications. The key products to be delivered include: Optimized clFRC prototypes capable of generating Tregs in vitro by tuning...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
This Project Grant award of $1,165,276 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund research to develop a novel biotherapeutic immunocytokine, F5111-IC, to suppress inhibitor formation in hemophilia patients. The primary awardee, Trustees of Indiana University, will investigate the F5111-IC treatment platform to promote immune tolerance and prevent the development of neutralizing antibodies against clotting factor replacement therapy...
The National Institute of General Medical Sciences (NIGMS) awarded a $917,454 Project Grant under CFDA 93.859, Biomedical Research and Research Training, to Integral Molecular Inc. The grant supports the development of a novel Membrane Proteome Array (MPA) technology for specificity screening and profiling of biotherapeutics like monoclonal antibodies and CAR-T cell therapies. The MPA represents 93% of the human extracellular proteome expressed in native conformation, providing a more...